Achilles Therapeutics plc

Achilles Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision T cell therapies to treat solid tumors. The company's approach utilizes the unique protein markers, called neoantigens, present on each individual's cancer cells. Achilles leverages its proprietary AI-powered platform, PELEUS™, to identify these clonal neoantigens and develop personalized cell therapies using the VELOS™ manufacturing process. This approach aims to create a clonal neoantigen-reactive T cell product, or cNeT, that targets multiple clonal neoantigens, ultimately destroying tumors without harming healthy tissues.

Achilles has two ongoing Phase I/IIa trials for their lead product: CHIRON, which targets advanced non-small cell lung cancer (NSCLC), and THETIS, which targets recurrent or metastatic melanoma. The company believes its precision therapy has the potential to significantly improve treatment outcomes for patients with a range of solid tumors.

Achilles Therapeutics is a biopharmaceutical company dedicated to transforming solid tumor cancer treatment through precision T cell therapies. They leverage AI-powered bioinformatics to identify clonal neoantigens, unique protein markers present on all cancer cells, and then develop personalized therapies that target these markers to destroy tumors without harming healthy tissues.

Achilles Therapeutics fosters a culture of innovation and collaboration, centered around developing cutting-edge precision T cell therapies to revolutionize cancer treatment. The company attracts and values top talent in the fields of cancer evolution, bioinformatics, and cell therapy, emphasizing a collaborative and interdisciplinary approach to research and development. With a strong commitment to ethical practices and patient well-being, Achilles fosters an environment that encourages open communication, intellectual curiosity, and a shared passion for making a positive impact on the lives of patients.